VIDEO: Turing Pharmaceuticals CEO Martin Shkreli: 5,000 Percent Price Boost ‘Not Excessive at All’
In case you hadn't heard, last month, Turing Pharmaceuticals CEO and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 per pill. Now he has a big public relations problem and a self-created health care crisis on his hands.In case you hadn’t heard, last month, Turing Pharmaceuticals chief executive and former hedge fund manager Martin Shkreli got hold of the rights to parasite-zapping drug Daraprim, and then he had the bright idea to raise the price from $13.50 to $750 a pill. Now he has a big public relations problem and self-created health care crisis on his hands. (Heck, he may even have the makings of a rap sheet.)
Shkreli has trotted out a number of tactics in response to the firestorm directed at him since news of the price hike broke. He’s gotten into ill-advised Twitter wars. He’s tried to reframe the astronomical boost in the cost of Daraprim as the product of philanthropy instead of the profit drive.
Watch as Shkreli tries, and fails, to cure the ensuing global epidemic of Daraprim sticker shock in an interview with CBS News:
–Posted by Kasia Anderson
AS CHAOS UNFOLDS, FIND SOLID GROUND…In this time of unprecedented challenges, independent journalism is more vital than ever. At Truthdig, we expose what power wants hidden and give you the clarity to make sense of it all.
Your donation helps ensure that truth telling continues.
TD Original
Gilead’s price drop for the HIV prevention drug lenacapavir is a smoke screen for monopoly medicine.
Health & Wellness
Community leaders in Mississippi and beyond race to limit the damage of governmental cuts to HIV care funding.
Film
A documentary tells the story of Carl Bean, a disco star who preached the gospel of love and acceptance at the height of the AIDS crisis.
Health & Wellness
A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence of the epidemic in the South.
Health & Wellness
Aging with HIV comes with an increased risk of health complications later in life. Is the U.S. health care system prepared to treat this growing population?
Opinion
A HIV survivor and former instructor reflects on his experiences.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.